FDA Issues a Reminder on Excipients in Dietary Supplements

January 21, 2014

In the new guidance on substances that can be added to foods, including beverages and dietary supplements, the FDA reminds manufacturers that the excipients added to oral dosage forms of these products need to “meet the same requirements as substances added to conventional foods.” This means that the substances added as fillers, coatings, antioxidants, disintegrants, etc. must be used either in accordance with a food additive regulation or be considered GRAS for the intended use. The only exceptions to the above are those substances excepted from the food additive definition.

The practice of relying on the presence of an excipient in the FDA’s Inactive Ingredient Database cannot assure that use of the same substance in a dietary supplement is acceptable. The risk-benefit balance accepted by the FDA for excipients in drugs is different than that for excipients in dietary supplements. For drugs, the FDA may find that short-term use or the serious nature of the disease a drug is intended to treat outweighs potential toxicity from an excipient. For dietary supplements, a similar level of excipient toxicity would not be tolerated when weighed against the potential for the long-term use of the supplement in a generally healthy population.

ProPharma Group is expert in assessing and qualifying the safety of excipients used in drugs and dietary supplements. Clients with questions are encouraged to call us to assist.

If you have any questions or thoughts on this blog post or others, please contact us.

Agency Alerts General Regulatory

May 19, 2016

Compassionate Use for Investigational Drugs: FDA to Improve Awareness & Transparency of Expanded Access Programs

The Reagan-Udall Foundation for the FDA (RUF), a non-profit organization created to help the FDA accomplish its mission, is in the process of developing an online Navigator to help patients and...

Read the Full Article
Agency Alerts General Regulatory

October 4, 2018

CBER Provides Sponsors with Policies & Procedures Regarding INTERACT Meetings

On Monday, October 1, FDA’s Center for Biologics Evaluation and Research (CBER) issued a document outlining the policies and procedures for scheduling and conducting INitial Targeted Engagement for...

Read the Full Article
General Regulatory Regulatory Sciences

March 31, 2015

Drug Development Questions And The FDA - The End Of The Black Hole

Commonly during drug development, significant issues arise for which FDA input is desired but that do not merit a full face-to-face multidisciplinary milestone meeting. In many cases, sponsors are...

Read the Full Article